Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcers Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Assistive ExoSkeletons to Enable Wearable Rehabilitation Robotics

NCT03717233
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus
Interventions
Exoskeleton
Device
Lead sponsor
Results Group LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

NCT00048347
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVONEX
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 26, 2026, 6:59 AM EDT
Terminated No phase listed Observational

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 26, 2026, 6:59 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion

NCT02382133
View directory record Official record
Conditions
Hypotension, Pressure Ulcer
Interventions
Nasal alar oxygen sensor
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 26, 2026, 6:59 AM EDT
Terminated Phase 4 Interventional

Evaluation of Health Costs and Resource Utilization

NCT01960426
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug
Other
Lead sponsor
University of Western Ontario, Canada
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 26, 2026, 6:59 AM EDT
Completed No phase listed Observational

Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease

NCT02054533
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of SNX-1012 in the Treatment of Oral Mucositis

NCT00385515
View directory record Official record
Conditions
Stomatitis, Oral Mucositis
Interventions
SNX-1012 (meclocycline sulfosalicylate), placebo
Drug
Lead sponsor
Mucosal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Rancho Mirage, California • Bridgeport, Connecticut • Norwich, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Oct 26, 2026, 6:59 AM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 73 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
10
States / cities
Anaheim, California • La Jolla, California • Oceanside, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 26, 2026, 6:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.

NCT01517516
View directory record Official record
Conditions
Irritable Bowel Syndrome, Cyclical Vomiting Syndrome, Ulcerative Colitis, Vulvodynia, Crohn's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 26, 2026, 6:59 AM EDT
Not listed Not applicable Interventional

Clinical Study Of Affinity Versus SOC In The Management Of VLUs

NCT04901013
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Affinity
Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Not applicable Interventional

Use of dHACM in the Treatment of Venous Leg Ulcers

NCT02011503
View directory record Official record
Conditions
Leg Ulcer
Interventions
Multi-layer compression therapy, Application of dHACM
Procedure · Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 26, 2026, 6:59 AM EDT
Terminated Not applicable Interventional

AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers

NCT01819142
View directory record Official record
Conditions
Pressure Ulcer
Interventions
AutoloGel
Device
Lead sponsor
Cytomedix
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pascagaula, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 26, 2026, 6:59 AM EDT
Not listed No phase listed Observational

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

NCT01658618
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
HP802-247
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 26, 2026, 6:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

NCT01143727
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Santyl, Tegaderm Hydrogel
Drug
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers

NCT01129986
View directory record Official record
Conditions
Venous Stasis Ulcers
Interventions
DermaStream
Device
Lead sponsor
EnzySurge
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 26, 2026, 6:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
48
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 26, 2026, 6:59 AM EDT
Terminated Not applicable Interventional

Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery

NCT03587519
View directory record Official record
Conditions
Ulcerative Colitis, Ileal Pouch, Ileostomy - Stoma
Interventions
Early, Late
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 26, 2026, 6:59 AM EDT
Recruiting Not applicable Interventional

Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

NCT07364630
View directory record Official record
Conditions
Diabetic Foot Ulcer, Foot Ulcer Chronic, DFU, Ulcer Foot, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, Leg Ulcers, Ulcer
Interventions
Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU
Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philidelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 26, 2026, 6:59 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 26, 2026, 6:59 AM EDT
Enrolling by invitation No phase listed Observational

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 6:59 AM EDT